VWAP | Jotup

Canadian Banc Corp. Monthly Dividend Declaration for Class A & Preferred Share

Retrieved on:

木曜日, 1月 18, 2024

The Company, Policy, Bank, Commerce, VWAP, National Bank of Canada, Bank of Montreal, National bank, Royal Bank of Canada, Toronto-Dominion Bank, Scotiabank

TORONTO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Canadian Banc Corp. (The "Company") declares its monthly distribution of $0.13138 for each Class A share and $0.06667 for each Preferred share.

Key Points:

TORONTO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Canadian Banc Corp. (The "Company") declares its monthly distribution of $0.13138 for each Class A share and $0.06667 for each Preferred share.
Distributions are payable February 9, 2024 to shareholders on record as at January 31, 2024.
As a result, Class A shareholders of record on January 31, 2024 will receive a dividend of $0.13138 per share based on the VWAP of $10.51 payable on February 9, 2024.
Since inception Class A shareholders have received a total of $21.57 per share and Preferred shareholders have received a total of $10.17 per share inclusive of this distribution, for a combined total of $31.74.

JPMorgan Files Registration Statement for Exchange Offer Relating to Its Alerian MLP Index ETNs

Retrieved on:

木曜日, 1月 18, 2024

Banking, Asset Management, Professional Services, Finance, JPMorgan Chase, CUSIP, VWAP, Prospectus, Exchange offer, Form, Sale, Exchange, Old, Register, Note, Security (finance)

JPMorgan Chase & Co. (“JPMorgan Chase” or the “Firm”) and JPMorgan Chase Financial Company LLC (“JPMorgan Financial”) announced today that they have filed a registration statement on Form S-4 (the “Registration Statement”) to register JPMorgan Financial’s proposed offer to exchange (the “Exchange Offer”) its newly offered Alerian MLP Index ETNs due January 28, 2044 (CUSIP: 48133Q309) (the “New Notes” ) for any and all outstanding Alerian MLP Index ETNs due May 24, 2024 (CUSIP: 46625H365) issued by JPMorgan Chase (the “Old Notes” and together with the New Notes, the “Alerian ETNs”).

Key Points:

JPMorgan Chase & Co. (“JPMorgan Chase” or the “Firm”) and JPMorgan Chase Financial Company LLC (“JPMorgan Financial”) announced today that they have filed a registration statement on Form S-4 (the “Registration Statement”) to register JPMorgan Financial’s proposed offer to exchange (the “Exchange Offer”) its newly offered Alerian MLP Index ETNs due January 28, 2044 (CUSIP: 48133Q309) (the “New Notes” ) for any and all outstanding Alerian MLP Index ETNs due May 24, 2024 (CUSIP: 46625H365) issued by JPMorgan Chase (the “Old Notes” and together with the New Notes, the “Alerian ETNs”).
Upon commencement of the Exchange Offer, JPMorgan Financial intends to give existing holders of the Old Notes (“Noteholders”) an opportunity to exchange their Old Notes for New Notes that mature on January 28, 2044, which provide similar exposure to the Alerian MLP Index® (the “Index”) as the Old Notes, subject to the terms and conditions set forth in the prospectus filed as part of the Registration Statement.
Noteholders will be able to tender Old Notes in exchange for New Notes only upon the effectiveness of the Registration Statement and the commencement of the Exchange Offer.
JPMorgan Financial expects to announce the expiration deadline, the exchange ratio and the settlement date for the Exchange Offer upon effectiveness of the Registration Statement and commencement of the Exchange Offer.

Kaman to be Acquired by Arcline for $1.8 Billion

Retrieved on:

金曜日, 1月 19, 2024

Other Manufacturing, Technology, Other Defense, Other Technology, Aerospace, Manufacturing, Other Health, Health, Defense, Slate, KAMN, VWAP, Morgan Stanley, History, Growth, Investment, Latham & Watkins, Kaman

Kaman Corp. (NYSE:KAMN) (“Kaman" or the “Company”) today announced that it has entered into a definitive agreement to be acquired by Arcline Investment Management, L.P. ("Arcline”), a growth-oriented private equity firm with deep experience investing in technology-driven, meaningful-to-the-world industrial businesses, in an all-cash transaction with a total enterprise value of approximately $1.8 billion.

Key Points:

Kaman Corp. (NYSE:KAMN) (“Kaman" or the “Company”) today announced that it has entered into a definitive agreement to be acquired by Arcline Investment Management, L.P. ("Arcline”), a growth-oriented private equity firm with deep experience investing in technology-driven, meaningful-to-the-world industrial businesses, in an all-cash transaction with a total enterprise value of approximately $1.8 billion.
Under the terms of the agreement, Kaman shareholders will receive $46.00 per share in cash.
Following its unanimous approval of the transaction, the Kaman Board of Directors recommends that Kaman shareholders vote in favor of the transaction.
Morgan Stanley & Co. LLC is serving as exclusive financial advisor to Arcline and Latham & Watkins LLP and Paul Hastings LLP are acting as legal counsel to Arcline.

Q4 Inc. Issues Final Reminder to Shareholders to Vote FOR the Proposed Acquisition by Sumeru Equity Partners

Retrieved on:

金曜日, 1月 19, 2024

Professional Services, Communications, Technology, Finance, Software, Public Relations, Investor Relations, Royal Bank of Canada, Circular, Essence, Arrangement, Special, Inc., Committee, VWAP, Glass Lewis, TSX, Telephone

A Special Meeting of Shareholders (the “Special Meeting”) related to the proposed Arrangement will be held on January 24, 2024 at 10:00 a.m. (Toronto Time).

Key Points:

A Special Meeting of Shareholders (the “Special Meeting”) related to the proposed Arrangement will be held on January 24, 2024 at 10:00 a.m. (Toronto Time).
Shareholders are urged to vote TODAY to ensure their vote is promptly received ahead of the voting deadline of January 22, 2024 at 10:00 a.m. Toronto Time.
Materials related to the Special Meeting and instructions on how to vote “FOR” the Arrangement can be found here: https://investors.q4inc.com/Special-Meeting-Vote/Special-Meeting/default... .
Under the terms of the Arrangement, Shareholders (other than Rolling Shareholders) will receive $6.05 a share in cash.

BestEx Research Launches IS Zero, Reinventing VWAP Algorithms for Low-Urgency Trading

Retrieved on:

水曜日, 1月 24, 2024

Alternative trading system, Awka South, VWAP, Algorithm, Research, AMS, Motivation, Mittal, Cryptocurrency

STAMFORD, Conn., Jan. 24, 2024 /PRNewswire/ -- BestEx Research Group LLC, a pioneer in high-performance algorithmic trading solutions, proudly announces the launch of IS Zero.

Key Points:

STAMFORD, Conn., Jan. 24, 2024 /PRNewswire/ -- BestEx Research Group LLC, a pioneer in high-performance algorithmic trading solutions, proudly announces the launch of IS Zero.
For decades, low-urgency orders have predominantly relied on VWAP algorithms for execution, which are tailored to track the market's average price rather than minimize IS.
This announcement follows the launch of the Adaptive Optimal framework last year, which empowers BestEx Research and its customers to build tailored liquidity-seeking algorithms.
BestEx Research customers are empowered to run A/B tests comparing IS Zero to VWAP with Strategy Studio, part of its award-winning Algorithm Management System (AMS).

MASON RESOURCES EMERGES AS STRATEGIC SHAREHOLDER OF NOUVEAU MONDE GRAPHITE THROUGH SALE OF LAC GUÉRET GRAPHITE PROPERTY

Retrieved on:

月曜日, 1月 22, 2024

Graphite, CO2, NMG, The Company, VWAP, Partnership, Innu, Sale, Pessamit, Acquisition, Mason, APA, NOU, Transport, TYO, First Nations

Fahad Al-Tamimi, Chairman of Mason, commented: "In forging this new strategic partnership with Nouveau Monde Graphite through this innovative structure, we pave the way for a thriving Québec graphite industry, a venture poised to yield substantial benefits for both Mason and Nouveau Monde shareholders.

Key Points:

Fahad Al-Tamimi, Chairman of Mason, commented: "In forging this new strategic partnership with Nouveau Monde Graphite through this innovative structure, we pave the way for a thriving Québec graphite industry, a venture poised to yield substantial benefits for both Mason and Nouveau Monde shareholders.
Arne H Frandsen, Chair of NMG, declared: "With its very large, high-quality natural graphite deposit, the acquisition of the Lac Guéret deposit represents a strategically important move by NMG.
This addition of a world-class asset to NMG's portfolio of resources, underpins the Company's growth prospects and commercial attractiveness.
We also warmly welcome Mason as a shareholder of NMG as we build a pioneering – and possibly the largest!

Q4 Inc. Issues Letter to Shareholders Reiterating Value-Maximizing Benefits of Proposed Acquisition by Sumeru Equity Partners

Retrieved on:

月曜日, 1月 15, 2024

Q4 Inc. (TSX:QFOR) (“Q4” or the “Company”), the leading capital markets access platform, today issued a letter to shareholders reiterating why they should support the proposed arrangement transaction (the “Arrangement”), whereby Q4 would be acquired by a newly formed entity controlled by Sumeru Equity Partners (“Sumeru”), a leading technology-focused investment firm.

Key Points:

Q4 Inc. (TSX:QFOR) (“Q4” or the “Company”), the leading capital markets access platform, today issued a letter to shareholders reiterating why they should support the proposed arrangement transaction (the “Arrangement”), whereby Q4 would be acquired by a newly formed entity controlled by Sumeru Equity Partners (“Sumeru”), a leading technology-focused investment firm.
At the Special Meeting, you will have an opportunity to vote on the proposed Arrangement (the “Arrangement”), whereby Q4 would be acquired by a newly formed entity controlled by Sumeru Equity Partners (“Sumeru”), a leading technology-focused investment firm.
From start to finish, the process was conducted over approximately 121 days – the agreement to transact with Sumeru was in no way rushed.
The fact that certain Shareholders agreed to roll allowed for a higher price to be offered to non-rolling Shareholders.

TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

Retrieved on:

火曜日, 1月 9, 2024

Patient, Therapy, Precision, Precision BioSciences, VWAP, GS, Economics, CD19, IND, Drug development, Pharmaceutical industry

Azer-cel is an allogeneic (off the shelf) CAR T program and the Company has near-term plans to evaluate the program in multiple autoimmune indications, with an investigational new drug (IND) filing targeted for mid-2024.

Key Points:

Azer-cel is an allogeneic (off the shelf) CAR T program and the Company has near-term plans to evaluate the program in multiple autoimmune indications, with an investigational new drug (IND) filing targeted for mid-2024.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are excited to expand our autoimmune portfolio and leverage our robust drug development and commercialization expertise in partnering with Precision on this CAR T program.
Under the terms of the agreement, TG Therapeutics will receive exclusive worldwide rights to develop and commercialize azer-cel in non-oncology indications, and in exchange, Precision will receive upfront and potential near-term economics valued at $17.5 million.
The upfront payment of $7.5 million will consist of cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the 30-day VWAP prior to purchase.

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Retrieved on:

火曜日, 1月 9, 2024

“We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.

Key Points:

“We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.
Precision will also receive $2.5 million within 12 months, as an equity investment in Precision’s common stock at 100% premium to the then 30-day VWAP prior to purchase.
Upon the achievement of certain near-term clinical milestones, Precision will receive an additional $7.5 million payment in cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the then current 30-day VWAP.
These transactions are expected to extend our runway and will fund continued development of our wholly owned in vivo gene editing programs.

Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for December 2023, includes Reg.-NMS Execution Statistics

Retrieved on:

火曜日, 1月 2, 2024

Professional Services, Finance, Samsung Galaxy Note 4, Samsung Galaxy Note 7, Investment, Darts, IBKR, Accumulated other comprehensive income, VWAP, Comprehensive income, Samsung Galaxy Note 3, FDIC

Note 1: Daily Average Revenue Trades (DARTs) – customer orders divided by the number of trading days in the period.

Key Points:

Note 1: Daily Average Revenue Trades (DARTs) – customer orders divided by the number of trading days in the period.
Note 2: FDIC insured client bank deposit sweep program balances with participating banks.
These deposits are not reported in the Company’s statement of financial condition.
More information, including historical results for each of the above metrics, can be found on the investor relations page of the Company’s corporate web site, www.interactivebrokers.com/ir .